Published in J Heart Lung Transplant on January 01, 2010
Gene delivery polymer structure-function relationships elucidated via principal component analysis. Chem Commun (Camb) (2015) 0.79
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation (2007) 4.67
Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med (2010) 4.31
Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol (2013) 2.92
Usefulness of routine periodic fasting to lower risk of coronary artery disease in patients undergoing coronary angiography. Am J Cardiol (2008) 2.10
Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail (2005) 1.99
Effects of the 2006 U.S. thoracic organ allocation change: analysis of local impact on organ procurement and heart transplantation. J Heart Lung Transplant (2009) 1.91
Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clin Chim Acta (2011) 1.83
Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol (2010) 1.81
Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. Circ Heart Fail (2009) 1.77
Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med (2009) 1.67
Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death? J Heart Lung Transplant (2010) 1.44
Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann Thorac Surg (2006) 1.43
Effect of ABO-incompatible listing on infant heart transplant waitlist outcomes: analysis of the United Network for Organ Sharing (UNOS) database. J Heart Lung Transplant (2009) 1.42
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
Improving outcomes with long-term "destination" therapy using left ventricular assist devices. J Thorac Cardiovasc Surg (2008) 1.39
Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J Heart Lung Transplant (2009) 1.37
Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol (2010) 1.34
Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail (2013) 1.19
Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet (2011) 1.19
End-of-life decision making and implementation in recipients of a destination left ventricular assist device. J Heart Lung Transplant (2010) 1.18
Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified? Circulation (2012) 1.14
Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation (2012) 1.11
Relation of heart failure hospitalization to exposure to fine particulate air pollution. Am J Cardiol (2008) 1.10
Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2011) 1.07
Prioritizing sensitized heart transplant candidates: a sensitive affair. J Heart Lung Transplant (2012) 1.06
Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol (2011) 1.04
Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant (2009) 1.03
Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J (2005) 0.99
Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. Transplantation (2014) 0.98
Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol (2007) 0.97
Experience with the Levitronix CentriMag in the pediatric population as a bridge to decision and recovery. Artif Organs (2009) 0.93
Electromagnetic interference of automatic implantable cardioverter defibrillator and HeartWare left ventricular assist device. ASAIO J (2013) 0.93
Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J Heart Lung Transplant (2009) 0.93
The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. Eur J Heart Fail (2010) 0.92
Characterization of diffuse fibrosis in the failing human heart via diffusion tensor imaging and quantitative histological validation. NMR Biomed (2014) 0.91
Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg (2007) 0.89
The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation. J Thorac Cardiovasc Surg (2010) 0.88
Nutrition assessment and management of left ventricular assist device patients. J Heart Lung Transplant (2005) 0.88
The intermountain risk score predicts incremental age-specific long-term survival and life expectancy. Transl Res (2011) 0.85
Left atrial sarcoma: resection and repair by cardiac autotransplant and in situ pericardial patch. Ann Thorac Surg (2006) 0.84
Longitudinal evaluation of microvessel density in survivors vs. nonsurvivors of cardiac pathologic antibody-mediated rejection. Cardiovasc Pathol (2012) 0.84
Effect of mechanical circulatory support on outcomes after heart transplantation. J Heart Lung Transplant (2005) 0.84
Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol (2006) 0.84
Outcome of noncardiac surgery in patients with ventricular assist devices. Am J Cardiol (2009) 0.83
Comparison of standard Maze III and radiofrequency Maze operations for treatment of atrial fibrillation. J Thorac Cardiovasc Surg (2007) 0.83
Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant (2007) 0.83
Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J Heart Lung Transplant (2007) 0.83
Superior predictive ability for death of a basic metabolic profile risk score. Am Heart J (2009) 0.83
Obesity and left ventricular assist device driveline exit site infection. ASAIO J (2010) 0.83
Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS). J Heart Lung Transplant (2010) 0.82
Transepicardial autologous bone marrow-derived mononuclear cell therapy in a porcine model of chronically infarcted myocardium. Cardiovasc Radiat Med (2005) 0.82
Randomized controlled trial of the efficacy of aerobic exercise in reducing metabolic risk in healthy older people: The Hertfordshire Physical Activity Trial. BMC Endocr Disord (2009) 0.82
Multivariate predictors of heart transplantation outcomes in the era of chronic mechanical circulatory support. Ann Thorac Surg (2007) 0.82
Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart Lung Transplant (2006) 0.81
A predictive instrument using contrast echocardiography in patients presenting to the emergency department with chest pain and without ST-segment elevation. J Am Soc Echocardiogr (2010) 0.81
Allograft rejection in patients supported with continuous-flow left ventricular assist devices. Ann Thorac Surg (2011) 0.81
A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. J Heart Lung Transplant (2008) 0.80
Differential impact on post-transplant outcomes between pulsatile- and continuous-flow left ventricular assist devices. Clin Transplant (2011) 0.80
A novel flexible endoluminal stapling device for use in NOTES colotomy closure: a feasibility study using an ex vivo porcine model. Surg Endosc (2011) 0.79
Left ventricular assist device malfunction: a systematic approach to diagnosis. J Am Coll Cardiol (2004) 0.79
Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant. J Heart Lung Transplant (2012) 0.79
A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2012) 0.79
Tricuspid valve replacement after cardiac transplantation. J Heart Lung Transplant (2005) 0.78
Surgical treatment of isolated (lone) atrial fibrillation with Gemini-S Ablation and Left Atrial Appendage Excision (GALAXY procedure). Innovations (Phila) (2012) 0.78
Impact of high-dose inotropic donor support on early myocardial necrosis and outcomes in cardiac transplantation. Clin Transplant (2011) 0.78
Excellent outcomes in a case of complex re-do surgery requiring prolonged cardioplegia using a new cardioprotective approach: adenocaine. J Extra Corpor Technol (2008) 0.78